Thank you to the #VJDementia and Dr. James Galvin for taking time out of a busy #ADPD2026 to discuss results from our Phase 2 study of #zervimesine in #dementia with Lewy bodies (DLB): lnkd.in/e_9Cw3N2.

#DementiaWithLewyBodies #DLBPsychosis #DementiaSupport #LewyStrong #Hallucinations #Delusions

$CGTX reported 4Q and YE2025 financial results last week: ir.cogrx.com/events/. During the webcast, CEO Lisa Ricciardi commented on the high level of interest in #zervimesine among participants in the DLB expanded access program.

#ClinicalResearch #DementiaWithLewyBodies #DLBPsychosis #LewyStrong

$CGTX reported 4QYE 2025 financial results this morning and conducted a live webcast: ir.cogrx.com/events/. Management discussed the plan to advance #zervimesine for the treatment of #psychosis associated with #dementia with Lewy bodies. #Pressrelease: tinyurl.com/23os8zbn

Behavioral and psychotic symptoms of #DLB are common and worsen over the disease course. $CGTX presented an analysis from Ph2 at #ADPD2026 showing that participants' psychotic symptoms stabilized with #zervimesine treatment (102% slowing of decline vs pbo on NPI-4). Poster: tinyurl.com/26e74vrq

The #CGTX team is presenting an analysis at #ADPD2026 showing that Phase 2 'SHIMMER' #DLB participants on #zervimesine had a 102% slowing of decline relative to placebo. #Pressrelease: tinyurl.com/26rh26be

#DementiaWithLewyBodies #LewyBodyDementia #Dementia #LewyStrong #Psychosis #Neuroscience